ZA200105473B - Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia. - Google Patents

Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia.

Info

Publication number
ZA200105473B
ZA200105473B ZA200105473A ZA200105473A ZA200105473B ZA 200105473 B ZA200105473 B ZA 200105473B ZA 200105473 A ZA200105473 A ZA 200105473A ZA 200105473 A ZA200105473 A ZA 200105473A ZA 200105473 B ZA200105473 B ZA 200105473B
Authority
ZA
South Africa
Prior art keywords
substituted
derivatives
utilisation
prophylaxis
therapy
Prior art date
Application number
ZA200105473A
Other languages
English (en)
Inventor
Gerd Steiner
Kurt Schellhaas
Wilfried Lubisch
Uta Holzenkamp
Dorothea Starck
Laszlo Szabo
Franz Emling
Garcia-Ladona Frasisco Javier
Hans-Peter Hofmann
Liliane Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA200105473B publication Critical patent/ZA200105473B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
ZA200105473A 1999-01-11 2001-07-03 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia. ZA200105473B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19900544A DE19900544A1 (de) 1999-01-11 1999-01-11 Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie

Publications (1)

Publication Number Publication Date
ZA200105473B true ZA200105473B (en) 2002-10-03

Family

ID=7893835

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200105473A ZA200105473B (en) 1999-01-11 2001-07-03 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia.

Country Status (19)

Country Link
EP (1) EP1140099A1 (zh)
JP (1) JP2002534467A (zh)
KR (1) KR20010101440A (zh)
CN (1) CN1333685A (zh)
AR (1) AR029741A1 (zh)
AU (1) AU2285100A (zh)
BG (1) BG105688A (zh)
BR (1) BR9916888A (zh)
CA (1) CA2359390A1 (zh)
DE (1) DE19900544A1 (zh)
HU (1) HUP0200520A3 (zh)
IL (1) IL144145A0 (zh)
MX (1) MXPA01006966A (zh)
NO (1) NO20013408L (zh)
PL (1) PL348916A1 (zh)
SK (1) SK9682001A3 (zh)
TR (1) TR200102009T2 (zh)
WO (1) WO2000041697A1 (zh)
ZA (1) ZA200105473B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
CN1856475A (zh) * 2003-09-23 2006-11-01 默克公司 异喹啉钾通道抑制剂
AU2006282403B2 (en) * 2005-08-26 2011-07-07 Institute Of Medicinal Molecular Design, Inc. Derivative having PPAR agonistic activity
NZ584098A (en) * 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
MA41168A (fr) 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
CN108484594B (zh) * 2018-02-09 2020-08-04 福建医科大学 一种烷氧基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (de) * 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
DE3831888A1 (de) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
JP3036789B2 (ja) * 1990-06-22 2000-04-24 三井化学株式会社 新規な複素環式化合物及び医薬組成物
DE19746612A1 (de) * 1997-10-22 1999-04-29 Basf Ag 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
IL144145A0 (en) 2002-05-23
AU2285100A (en) 2000-08-01
NO20013408L (no) 2001-08-21
BR9916888A (pt) 2001-11-20
WO2000041697A1 (de) 2000-07-20
HUP0200520A3 (en) 2003-04-28
NO20013408D0 (no) 2001-07-10
PL348916A1 (en) 2002-06-17
JP2002534467A (ja) 2002-10-15
AR029741A1 (es) 2003-07-16
BG105688A (en) 2002-02-28
HUP0200520A2 (hu) 2002-07-29
MXPA01006966A (es) 2002-04-10
TR200102009T2 (tr) 2002-01-21
KR20010101440A (ko) 2001-11-14
CN1333685A (zh) 2002-01-30
SK9682001A3 (en) 2002-03-05
DE19900544A1 (de) 2000-07-13
CA2359390A1 (en) 2000-07-20
EP1140099A1 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
HK1051695A1 (en) N6 heterocyclic 8-modified andenosine derivatives.
HUP0104917A3 (en) Azepinoindole derivatives, the production and use thereof
ZA200201494B (en) Benzodiazepin derivatives, the production and use thereof.
ZA200107989B (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof.
MXPA02008801A (es) Derivados de indol, proceso para la preparacion de los mismos y su uso.
ZA200006577B (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors.
IL148545A0 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
HK1047743A1 (en) New use and novel n-azabicyclo-amide derivatives.
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
HK1047588B (zh) 治療肥胖症的2-氧-4h-3，1-苯並噁嗪-4-酮
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
ZA200108905B (en) Use of macrolide compounds for the treatment of dry eye.
ZA200000362B (en) Stabilized metallocene polyolefins.
HK1049655A1 (en) Substituted norbornylamino derivatives, productionand use thereof and medicaments containing them.
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
PL343728A1 (en) Carbapenem derivatives, utilization thereof and intermediate compounds of the same
PL351616A1 (en) Polyolefin compositions, method for the production and use thereof
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200105473B (en) Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia.
MXPA01013465A (es) Uso de antagonistas de cortisol en el tratamiento de ataque al corazon.
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
ZA995212B (en) The use of aryl-cyclohexylamine derivatives against CNS disorders.
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
HUP9900123A3 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof
ZA200110351B (en) Bycyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof.